Advancing Health Outcomes: CoverMyMeds Supports Prior Authorization Reform Initiatives to Improve Patient Access

At CoverMyMeds, our mission is to help people get the medicine they need to live healthier lives. For over 15 years, we’ve been working to transform the prior authorization (PA) process, making it more efficient, transparent and patient-focused to get people the care they need faster. As a leader in electronic prior authorization (ePA) technology, we understand the complexities and challenges that come with the PA process. That’s why we’re committed to making a meaningful difference, alongside organizations such as the Centers for Medicare & Medicaid Services (CMS), to help improve health outcomes and streamline clinical workflows.

The reforms announced on June 23, 2025, by U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz build on previous rules and currently apply to medical and procedural PAs. We support the efforts of CMS, HHS, and leading payers for their commitment to improving patient access and reducing administrative burdens through PA reforms. These steps will help accelerate care decisions, reduce waste and enhance the patient and provider experience. As we learn more in the coming months, we’re prepared to adapt to any new opportunities, so patients can get on and stay on their treatment plans.

This momentum reflects the direction we’ve been moving in for years, fueled by our promise to keep the patient at the center of everything we do. Our ePA technology, which includes real-time prescription benefit and provider response cycles, is already in line with the proposed medical reforms. We’re also investing in advanced technologies like FHIR, as demonstrated by our recent acquisition of FastAuth. By integrating FastAuth’s automation and intelligence, we’re enhancing our abilities to streamline medical PAs and improve specialty access.

As our industry advances, interoperability will continue to play a critical role in modernizing the PA process, addressing the inefficiencies caused by fragmented systems and outdated workflows. Now more than ever, the need for increased collaboration across stakeholders is imperative, as highlighted in our 2025 Medication Access Report, and we’re well-positioned to drive this progress forward.

While it’s too early to assess the full impact of these voluntary commitments, we welcome the opportunity to support the operationalization of these changes as a market leader, and we'll evaluate ways we can support the implementation with minimal disruption to care delivery, to help ensure patients remain at the forefront of what we do.